Biotech

All Articles

Actinogen's cortisol blocker stops working phase 2 anxiety research

.Actinogen Medical's cortisol blocker has actually skipped the primary endpoint of a period 2 resear...

Bivictrix decides going personal only means to take ADC right into clinic

.Antibody-drug conjugates (ADCs) have actually been at the center of a lot of a billion-dollar biobu...

TPG tops up funds to $580M for investments all over lifestyle sciences

.Possession supervisor TPG, which has actually assisted biotechs like Sionna Therapies and also Sant...

Merck quits period 3 TIGIT test in bronchi cancer for futility

.Merck &amp Co.'s TIGIT plan has actually suffered yet another problem. Months after shuttering a pe...

After a tough year, Exscientia folds up right into Recursion

.After a year defined through pipe hairstyles, the shift of its own CEO and discharges, Exscientia w...

Cullinan, after $25M deal, hands back bispecific to Port

.Cullinan Rehab was wowed sufficient with Harbour BioMed's bispecific invulnerable reactor that it h...

A deeper take a look at Intense Biotech's Ferocious 15

.In this particular week's incident of "The Top Pipe," our team are actually diving right into Feroc...

Lilly experiences stage 2 failure of tau-targeting med

.The confetti is still flying coming from Eli Lilly's celebration commemorating the approval of Alzh...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of significant leadership hirings, firings a...

Lykos will definitely ask FDA to reassess its choice adhering to being rejected of MDMA treatment for trauma

.Adhering to an inadequate showing for Lykos Therapeutics' MDMA applicant for trauma at a latest FDA...